trial

Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study

NCTId NCT07153835
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 505 (estimated)
Sponsored by Sher-E-Bangla Medical College
Primary completion 2026-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
505 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-09-01
Primary completion
2026-03-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Sher-E-Bangla Medical CollegeLead Sponsor
ACI PharmaceuticalsCollaborator
US-Bangla Medical College HospitalCollaborator
Dr. M M Jalal UddinCollaborator
Dr.Ahsan Aziz SarkarCollaborator

Investigators

1
Dr. M M Jalal Uddin Co-invetigator, MBBS,FCPS (Psychiatry), MPHStudy Director

Sites

1 total
Barishal, Bangladesh

Facts & assertions

4 sourced
Enrollment
505
Phase
PHASE4
Primary Completion Date
2026-03-31
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Sher-E-Bangla Medical College
company
collaborator
ACI Pharmaceuticals
company
US-Bangla Medical College Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dr. M M Jalal Uddin Co-invetigator, MBBS,FCPS (Psychiatry), MPH
person